Unknown NA INTERVENTIONAL 2-arm NCT03792152

A Trial of Rivaroxaban Versus Warfarin in Dissolving Left Atrial Appendage Thrombus in Patients With Atrial Fibrillation

A Prospective Randomized Controlled Trial of Rivaroxaban Versus Warfarin in Dissolving Left Atrial Appendage Thrombus in Patients With Atrial Fibrillation

Sponsor: The Second Affiliated Hospital of Chongqing Medical University

Conditions Atrial Fibrillation Left Atrial Appendage Thrombosis Rivaroxaban

Interventions Rivaroxaban Warfarin

Updated 6 times since 2019 Last updated: Mar 18, 2019 Started: Jun 1, 2019 Primary completion: Jan 1, 2022 Completion: Dec 30, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03792152, this NA trial focuses on Atrial Fibrillation and Left Atrial Appendage Thrombosis and remains ongoing. Sponsored by The Second Affiliated Hospital of Chongqing Medical University, it has been updated 6 times since 2019, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown NA
Jul 2024 — Sep 2024 [monthly]

Unknown NA

Status: Unknown Status → Unknown
Feb 2023 — Jul 2024 [monthly]

Unknown Status NA

Status: Not Yet Recruiting → Unknown Status
Jan 2021 — Feb 2023 [monthly]

Not Yet Recruiting NA
Apr 2019 — Jan 2021 [monthly]

Not Yet Recruiting NA

▶ Show 1 earlier version

Feb 2019 — Apr 2019 [monthly]

Not Yet Recruiting NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

The Second Affiliated Hospital of Chongqing Medical University

Data source: The Second Affiliated Hospital of Chongqing Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.